# US 2016/0252494 A1 · Microscale micropatterned engineered in vitro tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252494 A1
- Document ID: US20160252494A1
- Status: Published application
- Kind: A1
- Application number: 14/867,909
- Filed: 2015-09-28
- Published: 2016-09-01
- Earliest claimed: 2005-05-24
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Sangeeta N. BHATIA; Salman R. KHETANI
- Web page: https://patentgrep.com/patent/US20160252494A1

## CPC

- G01N 33/5023: {on expression patterns}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0656: {Adult fibroblasts}
- C12N 5/067: {Hepatocytes}
- C12N 5/0671: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- G01N 33/5014: {for testing toxicity}
- G01N 33/5067: {Liver cells}
- C12N 2502/13: connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N 2502/1323: Adult fibroblasts
- C12N 2533/54: Collagen; Gelatin
- C12N 2535/10: Patterned coating
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides an in vitro culture systems. The invention provides methods and systems useful for developing in vitro an engineered tissue, method of using the tissue and compositions comprising the tissue.

## Claims

### Claim 1

An in vitro cellular composition, comprising:
(a) one or more populations of parenchymal cells defining a cellular island; and
(b) a population of non-parenchymal cells, wherein the non-parenchymal cells define a geometric border of the cellular island.

### Claim 2 (depends on 1)

The in vitro cellular composition of claim 1, wherein the parenchymal cells are selected from the group consisting of hepatocytes, pancreatic cells (alpha, beta, gamma, delta), myocytes, enterocytes, renal epithelial cells, brain cells (neurons, astrocytes, glial cells), respiratory epithelial cells, adult and embryonic stem cells, and blood-brain barrier cells.

### Claim 3 (depends on 1)

The in vitro cellular composition of claim 1, wherein the parenchymal cells are hepatocytes.

### Claim 4 (depends on 1)

The in vitro cellular composition of claim 1, wherein the non-parenchymal cells are stromal cells.

### Claim 5 (depends on 4)

The in vitro cellular composition of claim 4, wherein the stromal cells are fibroblast cells or fibroblast derived cells.

### Claim 6 (depends on 1)

The in vitro cellular composition of claim 1, wherein the cellular islands comprise a diameter or width of about 250 μm to 750 μm.

### Claim 7 (depends on 1)

The in vitro cellular composition of claim 1, wherein the cellular islands are spaced apart from about 2 μm to 1300 μm from center to center of the cellular islands.

### Claim 8 (depends on 1)

The in vitro cellular composition of claim 1, located in a microfluidic device.

### Claim 9 (depends on 1)

The in vitro cellular composition of claim 1, located in a tissue culture plate.

### Claim 10 (depends on 1)

The in vitro cellular composition of claim 1, wherein the parenchymal cells are human cells.

### Claim 11 (depends on 1)

The in vitro cellular composition of claim 1, wherein the non-parenchymal cells are human cells.

### Claim 12 (depends on 1)

The in vitro cellular composition of claim 1, wherein the parenchymal and non-parenchymal cells are human cells.

### Claim 13 (depends on 1)

The in vitro cellular composition of claim 1, wherein the cellular island is three-dimensional.

### Claim 14 (depends on 13)

The in vitro cellular composition of claim 13, wherein the cellular island is a spheroid.

### Claim 15 (depends on 1)

The in vitro cellular composition of claim 1, wherein the cellular island comprises parenchymal cells in a bounded geometry bordered by non-parenchymal cells.

### Claim 16

A method of making a plurality of cellular islands on a substrate, comprising:
(a) spotting an adherence material on a substrate at spatially different locations each spot having a defined geometric size and/or shape;
(b) contacting the substrate with a population of cells that selectively adhere to the adherence material and/or substrate; and
(c) culturing the cells on the substrate to generate a plurality of cellular islands.

### Claim 17 (depends on 16)

The method of claim 16, wherein the spotting is performed by lithographic techniques.

### Claim 18 (depends on 17)

The method of claim 17, wherein the lithographic technique is photolithography.

### Claim 19 (depends on 16)

The method of claim 16, wherein the adherence material is selected from the group consisting of an extracellular matrix material, a sugar, a proteoglycan and any combination thereof.

### Claim 20 (depends on 16)

The method of claim 16, wherein the population comprises a parenchymal cell population that selective adheres to the adherence material.

### Claim 21 (depends on 16)

The method of claim 16, wherein the population comprises two or more cell types that selectively adhere to different locations or materials on the substrate.

### Claim 22 (depends on 20)

The method of claim 20, wherein the parenchymal cell population is selected from the group consisting of hepatocytes, pancreatic cells (alpha, beta, gamma, delta), myocytes, enterocytes, renal epithelial cells, brain cells (neurons, astrocytes, glial cells), respiratory epithelial cells, adult and embryonic stem cells, and blood-brain barrier cells.

### Claim 23 (depends on 20)

The method of claim 20, wherein the parenchymal cell population comprises hepatocytes.

### Claim 24 (depends on 20)

The method of claim 20, further comprising contacting the substrate with a population that adheres to the substrate at a location different than the parenchymal cell population.

### Claim 25 (depends on 24)

The method of claim 24, wherein the population comprises stromal cells.

### Claim 26 (depends on 25)

The method of claim 25, wherein the stromal cells are fibroblast or fibroblast derived cells.

### Claim 27 (depends on 16)

The method of claim 16, wherein the substrate is a tissue culture substrate.

### Claim 28 (depends on 16)

The method of claim 16, wherein the substrate is glass or polystyrene.

### Claim 29 (depends on 16)

The method of claim 16, wherein the defined diameter is about 250 μm to 750 μm.

### Claim 30 (depends on 16)

The method of claim 16, wherein the spots are spatially separated by about 2 μm to 1300 μm.

### Claim 31 (depends on 16)

A cellular composition made by the method of claim 16.

### Claim 32

An assay system comprising:
contacting an artificial tissue comprising parenchymal cells having a bounded geometry bordered by non-parenchymal cells wherein the bounded geometry has at least one dimension from side to side of the bounded geometry of about 250 μm to 750 μm;
contacting the artificial tissue with a test agent; and
measuring an activity selected from gene expression, cell function, metabolic activity, morphology, and a combination thereof, of the artificial tissue.

### Claim 33 (depends on 32)

The assay system of claim 32, wherein the test agent is selected from an infectious agent is selected from an infectious agent, a protein, a peptide, a polypeptide, an antibody, a peptidomimetic, a small molecule, an oligonucleotide, and a polynucleotide.

### Claim 34 (depends on 32)

The assay system of claim 32, wherein the test agent is a cytotoxic agent.

### Claim 35 (depends on 32)

The assay system of claim 32, wherein the test agent is a pharmaceutical agent.

### Claim 36 (depends on 32)

The assay system of claim 32, wherein the test agent is a xenobiotic.

### Claim 37 (depends on 36)

The assay system of claim 36, wherein the xenobiotic is selected from the group consisting of an environmental toxin, a chemical/biological warfare agent, a natural compound and a nutraceutical.

### Claim 38 (depends on 32)

The assay system of claim 32, wherein the activity is adsorption, distributions, metabolism, excretion, and toxicology (ADMET) of the test agent.

### Claim 39 (depends on 32)

The assay system of claim 32, wherein the metabolic activity is protein production.

### Claim 40 (depends on 32)

The assay system of claim 32, wherein the metabolic activity is enzyme bioproduct formation.

### Claim 41 (depends on 32)

The assay system of claim 32, wherein the parenchymal cells are human hepatocytes and the non-parenchymal cells are fibroblasts.

### Claim 42

An artificial tissue comprising islands of parenchymal cells surrounded by stromal cells wherein the islands of parenchymal cells are about 250 μm to 750 μm in diameter or width.

### Claim 43 (depends on 42)

The artificial tissue of claim 42, wherein the parenchymal cells are human hepatocytes and the stromal cells are fibroblasts.

### Claim 44

A method of producing a tissue in vitro, comprising:
seeding a first population of cells on a substrate having defined regions for attachment of the first population of cells, wherein the defined regions comprise a bounded geometric dimension of about 250 μm to 750 μm;
seeding a second population of cells on the substrate, such that the second population of cells surround or adhere adjacent to the first population of cells; and
culturing the cells under conditions and for a sufficient period of time to generate a tissue.

### Claim 45 (depends on 44)

The method of claim 44, wherein the first population of cells comprise human hepatocytes and the second population of cells comprise stromal cells.

### Claim 46 (depends on 45)

The method of claim 45, wherein the stromal cells are fibroblasts.
